阿里健康(00241.HK):遭阿里(09988.HK)減持為假消息
阿里健康(00241.HK)於官方微博表示,針對有報道指阿里(09988.HK)減持公司股份約1.54億股,持股降至67.51%為假消息,呼籲市場釐清基礎事實。
據聯交所權益披露資料顯示,雲鋒基金透過旗下的 Innovare Tech Limited ,於上周二(14日)以平均價每股22.65元,售出近1.54億股阿里健康股份,涉及約34.88億元,雲鋒基金持股降至約32.3%。雲鋒基金由阿里巴巴創辦人馬雲與好友虞鋒共同創立,主要投資電訊、科技及媒體等行業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.